Unfavorable economic conditions and increasingly savvy investment in the autism industry have compressed earnings valuations. Still, the autism segment remains one of health care’s most desirable investment spaces.
Over the last three years, low-end and high-end multiples have been higher than a decade ago. Yet, they reflect a comedown following a deal volume and valuations spike, Behavioral Health Business reports.
Multiples ranged from 5.75 times earnings to 14 times earnings from the middle of 2016 to the middle of 2019, Dexter Braff said at the Autism Investor Summit. Braff is the president of M&A advisory firm The Braff Group. Read more.
